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respondents were considerably less willing to trade off 
time to avoid pain/discomfort than the UK respondents; for 
example, moving from health state, 11121 (some problems 
with pain/discomfort) to 11131 (extreme pain/discomfort) 
represented a decrement of 0.65 on the observed TTO 
value in the UK compared with 0.15 in Japan. Using the 
EQ-5D-5L, Japanese respondents were also less willing to 
trade off time to avoid pain/discomfort than respondents 
in England; however, the difference in values was much 
smaller than that observed using EQ-5D-3L data.
Conclusions This study provides evidence of between-
country differences in the self-reporting and valuation of 
health, including pain/discomfort, when using EQ-5D in 
general population samples. The results suggest a need 
for caution when comparing or aggregating EQ-5D self-
reported data in multi-country studies.
Keywords Patient-reported outcomes · EQ-5D · 
Self-reported pain/discomfort · Health state valuation · 
Between-country comparison
Introduction
Patient-reported outcomes (PROs) are widely used as 
outcome measures in clinical trials of pain treatments. 
Indeed, given that pain can only be measured subjec-
tively, studies of pain are entirely reliant on self-reporting 
[1]. The assessment of pain is incorporated in different 
ways in PROs, ranging from generic measures of health-
related quality of life, such as EQ-5D [2] in which pain/
discomfort is only one of five dimensions measured, to 
tools that are specific to the assessment of pain, such as 
the Brief Pain Inventory [3]. One important consideration 
when using such measures in multi-country studies is that 
Abstract 
Purpose To investigate the systematic differences in the 
self-reporting and valuation of overall health and, in par-
ticular, pain/discomfort between three countries (England/
UK, Japan, and Spain) on the EQ-5D.
Methods Existing datasets were used to explore dif-
ferences in responses on the EQ-5D descriptive system 
between Japan (3L and 5L), the UK (3L), England (5L), 
and Spain (5L), particularly on the dimension of pain/dis-
comfort. The role of different EQ dimensions in determin-
ing self-reported overall health scores for the EuroQol vis-
ual analog scale (EQ-VAS) was investigated using ordinary 
least squares regression. Time trade-off (TTO) results from 
Japanese and UK respondents for the EQ-5D-3L as well as 
Japanese and English respondents for the EQ-5D-5L were 
compared using t tests.
Results For the EQ-5D-3L, a higher percentage of 
respondents in Japan than in the UK reported ‘no pain/dis-
comfort’ (81.6 vs 67.0%, respectively); for the EQ-5D-5L, 
the proportions were 79.2% in Spain, 73.2% in Japan, and 
63–64% in England, after adjusting for age differences in 
samples. The ‘pain/discomfort’ dimension had the larg-
est impact on respondents’ self-reported EQ-VAS only 
for EQ-5D-3L in Japan. Using the EQ-5D-3L, Japanese 
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factors such as race, ethnicity, language, and culture can 
potentially affect responses to PRO instruments [4–6].
With regard to pain reporting, there is evidence that 
this can vary quite widely across countries; for example, 
the results of a survey published in 2014 showed that 
pain reporting and treatment rates were lower in China 
(6.2% and 28.3%, respectively) and Japan (4.4% and 
26.3%, respectively) than in the other countries involved 
(≥14.3% and 35.8%, respectively) [7]. Substantial vari-
ations between countries in the rate of pain reporting 
have also been reported in primary care [8] and among 
patients with cancer [9]. Within Europe, studies have 
also shown variation in pain reporting; using the pain/
discomfort dimension of the EQ-5D, rates of respondents 
declaring no pain/discomfort varied from 65% in France 
to 79.5% in Spain [10]. At least some of the difference 
between countries may depend on cultural differences in 
pain response rather than on differences in objective lev-
els of pain. For example, in experimental studies, Japa-
nese subjects provided lower pain ratings for equivalent 
‘objective’ levels of pain than European subjects [11], 
whereas other studies have shown that Euro-Americans 
consider seeking pain relief more acceptable than Japa-
nese respondents [12]. However, evidence from Uki et al. 
suggests that Japanese patients with cancer reported high 
levels of pain with inadequate pain management [13].
The EQ-5D is one of the most widely used generic 
preference-based measures of health status. It has been 
translated into numerous languages and is available in 
an increasing number of country-specific utility-based 
value sets. Nevertheless, little attention has been paid to 
whether the effects described earlier in relation to pain 
affect the self-rating and valuation of pain/discomfort 
on EQ-5D and whether such data can be compared and 
aggregated across countries. In one of the few such anal-
yses performed, Tsuchiya et  al. compared the results of 
the UK and Japanese EQ-5D-3L valuation data and noted 
that the two datasets were positively correlated [14]. Fur-
thermore, Japanese time trade-off (TTO) values were 
consistently higher than those from the UK, except for 
mild states.
The availability of self-reported and valuation EQ-
5D-3L data from Japan and the UK together with self-
reported and valuation data from England and Japan for 
the latest version of the instrument, the EQ-5D-5L, makes 
it possible to explore these questions in more depth. Self-
reported data were also available for the EQ-5D-5L from 
Spain. The primary aim of this study was to investigate 
whether available EQ-5D data provide evidence of system-
atic differences in the way respondents in Japan self-report 
and value health using EQ-5D compared with respondents 
from England/UK and Spain, with a particular focus on the 
pain/discomfort dimension.
Methods
The EQ-5D
The EQ-5D consists of a descriptive system and a visual 
analog scale (EQ-VAS). Respondents rate their health 
on the EQ-5D descriptive system and assess their overall 
health on the EQ-VAS.
There are two versions of the instrument for use in the 
adult population, EQ-5D-3L and EQ-5D-5L. Both meas-
ure health using a descriptive system with five dimensions 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression). The original version of EQ-5D (EQ-
5D-3L) uses three levels of severity (no, some, extreme 
problems or unable to) in each dimension. To increase the 
instrument’s sensitivity, a new version of the instrument 
(EQ-5D-5L) was developed with five levels of severity 
(no, slight, moderate, severe, extreme problems or unable 
to) [15]. Self-ratings on the descriptive system are summa-
rized as a five-number ‘code’ where each number reflects 
the severity level on the individual dimensions. Each ‘code’ 
represents a unique health state, with the state 11111 repre-
senting full health. There are 243 EQ-5D-3L health states 
(243 = 35) and 3125 EQ-5D-5L health states (3125 = 55). 
By selecting one level of severity in each dimension on 
either version of the EQ-5D, respondents assign themselves 
one out of all possible health states as a description (known 
as a ‘profile’) of their own health.
The EQ-VAS consists of a vertical scale with anchor 
points of 0 (worst possible health) and 100 (best possible 
health). The respondent marks a point on the scale to show 
how they perceive their overall health.
In addition to providing these two types of self-reported 
data, the EQ-5D is frequently used in conjunction with 
health state valuation techniques such as TTO or discrete 
choice experiments to generate preference-based societal 
weights for each of the individual health states generated by 
the descriptive system [16]. It is recommended that weights 
be obtained for individual countries, as values assigned to 
health states might differ between countries for cultural or 
other reasons [17].
Data
Valuation and self-reported health data obtained from the 
EQ-5D-3L valuation surveys in the UK and Japan as well 
as EQ-5D-5L valuation surveys in England and Japan were 
used [14, 18–20]. At the time the present study was carried 
out, self-reported health data on EQ-5D-5L were also avail-
able for Spain [21]. In all cases, the samples included were 
intended to be representative of the general population of 
the country.
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Socio-demographic and health-related characteristics 
available in each of the five datasets included age, gender, 
and respondents’ experience of serious illness (in them-
selves, a family member, or others). The same background 
characteristics were recorded in each of the five datasets.
The Japanese EQ-5D-3L valuation study was a quasi-
replication of the UK valuation study [14]. Each respond-
ent valued the same set of the 17 health states, which were 
a subset of the 42 health states in the UK study [18]. The 
EQ-5D-5L valuation data used in the present analysis were 
collected during valuation studies carried out in Japan, 
England, and Spain using the EuroQol valuation technol-
ogy (EQ-VT) software, which was developed specifically 
for the EQ-5D-5L value set studies [16]. An identical meth-
odology based on computer-assisted personal interviews 
(CAPI) was used in all countries. Each respondent was 
asked to provide TTO values for a block of 10 health states 
out of the 86 health states selected for direct valuation. 
All interviewers received training on administration of the 
CAPI and EQ-VT. Only the observed TTO values (rather 
than the value sets modeled from those data) were used in 
this study.
A summary of the characteristics of each survey is pro-
vided in Table 1.
Statistical analysis
There were five parts to the statistical analysis. First, 
respondents’ socio-demographic and health-related char-
acteristics were compared across the five datasets. Second, 
self-reported data on the descriptive systems of EQ-5D-3L 
and EQ-5D-5L were compared to investigate whether there 
were systematic differences between countries that could 
not be explained by differences in sample characteristics on 
age or gender, particularly in regard to reporting of pain/
discomfort. Third, the impact of the five dimensions of 
the descriptive system on EQ-VAS scores was analyzed to 
determine, in particular, the contribution of the pain/dis-
comfort dimension to VAS scoring. Fourth, valuation data 
were used to explore whether respondents in Japan and the 
UK for the EQ-5D-3L valuation studies and respondents 
in Japan and England for the EQ-5D-5L valuation studies 
have different stated preferences in terms of their willing-
ness to trade off time in TTO tasks, particularly in relation 
to health states involving pain/discomfort. Fifth, the linked 
self-reported and valuation datasets for the EQ-5D-3L and 
EQ-5D-5L valuation studies in the UK/England and Japan 
were analyzed to investigate whether there was any rela-
tionship between respondents’ self-reported pain/discom-
fort and the TTO values they assigned to the hypothetical 
health states.
The socio-demographic and health-related characteris-
tics of the different samples were compared using t tests 
for age, and chi-squared tests for gender and the propor-
tions of respondents who reported having experienced 
serious illness in themselves, a family member, or others.
Respondents’ self-reported EQ-5D data were analyzed 
by comparing the distribution of EQ-5D profile data by 
country and instrument version. The ceiling effect (meas-
ured by the proportion of respondents reporting the best 
possible health for EQ-5D), the number of EQ-5D pro-
files used, and the distribution of responses by dimension 
were also calculated and compared across countries and 
EQ-5D versions. Adjustments for age and gender were 
made when comparing distributions on the descriptive 
system across countries. Using England as an example, 
to adjust for age difference, five age ranges were used 
(≤30, 31–45, 46–60, 61–75, and >75 years). For each 
age range, the proportion of respondents in England 
who reported full health was calculated followed by the 
weighted average of the five proportions. The weight for 
each age band is the proportion of respondents in that age 
band in Spain or Japan. Adjustments for any differences 
in gender distributions were made in the same way.
The extent to which responses on the five dimensions 
of the descriptive system explained self-reported overall 
health on the EQ-VAS was examined using ordinary least 
squares (OLS) regression methods and the results were 
compared between countries for both the 3L and 5L. Data 
on the five dimensions of the EQ-5D were recorded as 
continuous variables (1 for level 1, 2 for level 2, 3 for 
level 3, 4 for level 4, and 5 for level 5). To show the mod-
el’s goodness of fit, adjusted R-squared and results from 
residual analysis were reported after each regression.
To explore whether there were differences in TTO val-
ues in the valuation studies between respondents, in par-
ticular for pain/discomfort, EQ-5D-3L and EQ-5D-5L 
valuation data from the UK/England and Japan were ana-
lyzed. Respondents in the UK and Japan in the EQ-5D-3L 
studies yielded observed values for 42 health states in the 
UK and 17 health states in Japan. The EQ-5D-5L stud-
ies in Japan and England yielded observed values for 86 
health states. TTO values in each version of the EQ-5D 
for those health states were compared between the two 
countries using t tests.
Among the 17 hypothetical health states in the EQ-
5D-3L valuation data, there were three pairs of health 
states that only differed on the pain/discomfort dimen-
sion. Among the 86 hypothetical health states in the EQ-
5D-5L valuation data, there were seven pairs of health 
states that only differed on the pain/discomfort dimen-
sion. For each version of the EQ-5D valuation stud-
ies, the difference in mean TTO values was compared 
between respondents by country (for those pairs that only 
differed in the pain/discomfort dimension) to gain insight 
into differences in how respondents in Japan and the UK/
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England value EQ-5D health states with respect to the 
pain/discomfort dimension.
Finally, respondents’ self-reported and valuation data 
were linked using respondents’ ID for the EQ-5D-3L and 
EQ-5D-5L data from Japan and the UK/England. Using 
both the self-reported and valuation data, the effect of self-
reported pain/discomfort in explaining the TTO values was 
explored using the OLS regression analyses to model the 
TTO values for the five dimensions of the EQ-5D profile 
and self-reported pain/discomfort. All analyses were per-
formed using STATA/MP 13.
Results
There was no statistically significant difference in mean 
age between respondents in the UK and Japan in the EQ-
5D-3L data (P = 0.753), although the UK sample had a 
higher proportion of females and respondents who had 
experienced serious illness in themselves or in a fam-
ily member, and a lower proportion of respondents who 
had taken care of others with a serious illness (P < 0.05). 
There was no statistically significant difference in mean 
age between respondents in Japan and Spain in the EQ-
5D-5L datasets (P = 0.119); however, respondents in 
England were older than respondents in Japan and Spain 
(P < 0.05). The English sample also reported the highest 
proportion of females and respondents who had experi-
enced serious illness themselves, in a family member, 
or who had taken care of others with a serious illness 
(P < 0.05) (Table 2).
The most frequently self-reported profile using both 
versions of the EQ-5D was full health. The proportion of 
respondents reporting full health was highest in Japan for 
both versions of the EQ-5D, and the differences between 
other countries were statistically significant (P < 0.05). 
After adjusting for differences in age and gender in the 
EQ-5D-5L samples, the proportion of those report-
ing full health was still highest among respondents in 
Japan (66.5%), followed by Spain (54.9%) and England 
(53.8%). The reduction in the ceiling effect using the EQ-
5D-5L compared with the EQ-5D-3L was similar in the 
Table 2  Socio-demographic and health-related characteristics of respondents in Japan and the UK for the EQ-5D-3L; Japan, England, and 
Spain for the EQ-5D-5L
SD standard deviation
a This category includes missing values
b Respondents who had experienced serious illness in themselves
c Respondents who had experienced serious illness in a family member
d Respondents who had taken care of others with a serious illness
Respondent characteristics EQ-5D-3L EQ-5D-5L
Japan (n = 543) UK (n = 3395) P value Japan (n = 1026) England (n = 996) Spain (n = 1000) P value
Age, years, mean (SD) 48.1 (15.3) 47.9 (18.4) 0.753 44.9 (14.9) 51.2 (17.9) 43.8 (17.3) 0.000 
(Spain, 
England)
0.000 
(Japan, 
England)
0.119 
(Japan, 
Spain)
Gender (%)
 Female 230 (42.4) 1926 (56.7) 0.000 511 (49.8) 591 (59.3) 525 (52.5) 0.000
 Male 313 (57.6) 1469 (43.3) 515 (50.2) 405 (40.7) 475 (47.5)
Experience of serious illness (self)b (%)
 Yes 80 (14.7) 1076 (31.7) 0.000 192 (18.7) 330 (33.1) 144 (14.4) 0.000
 Noa 463 (85.3) 2319 (68.3) 834 (81.3) 666 (66.9) 856 (85.6)
Experience of serious illness (family)c (%)
 Yes 188 (34.6) 2156 (63.5) 0.000 377 (36.7) 692 (69.5) 633 (63.3) 0.000
 Noa 355 (65.4) 1239 (36.5) 649 (63.3) 304 (30.5) 367 (36.7)
Experience of serious illness (other)d (%)
 Yes 178 (32.8) 547 (16.1) 0.000 130 (12.7) 416 (41.8) 347 (34.7) 0.000
 Noa 365 (67.2) 2848 (83.9) 896 (87.3) 580 (58.2) 653 (65.3)
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UK/England (from 56.9% to 47.6% for the EQ-5D-3L 
and EQ-5D-5L, respectively) and Japan (from 77.2% to 
66.5%).
Analysis of self-reported EQ-5D profile data showed 
that Japanese respondents employed a much smaller num-
ber of health profiles than respondents in other coun-
tries. Among the EQ-5D-3L datasets, three health states 
accounted for 90.1% of Japanese respondents compared 
with 12 health states in the UK (90.6%). The difference 
is even more marked for the EQ-5D-5L, where only four 
health states accounted for 91.4% of Japanese respondents 
compared with 80 health states in England (90.1%) and 16 
health states in Spain (90.0%). Full EQ-5D profile distri-
butions by country and EQ-5D version are available upon 
request from the authors.
Figure  1 shows the proportion of respondents report-
ing level one for the EQ-5D-3L by dimension and country. 
In the pain/discomfort dimension, 81.6% of respondents 
in Japan self-reported level one, compared with 67.0% of 
respondents in the UK. Figure 2 shows that more respond-
ents in Japan self-reported level one for the EQ-5D-5L 
than in England and Spain in four dimensions. In the pain/
discomfort dimension, a higher proportion of respond-
ents in Spain (79.2%) self-reported level one than in Japan 
(73.2%) and England (58.4%), although after adjusting for 
differences in age and gender between the samples, the 
proportion of respondents reporting level 1 on the pain/dis-
comfort dimension in England was approximately 64%.
The results of modeling respondents’ EQ-VAS scores 
as a function of their self-reported EQ-5D profiles are 
shown in Table  3. EQ-VAS scores decreased when the 
severity of problems increased in any of the five dimen-
sions, and this finding was consistent across countries and 
EQ-5D versions. Using EQ-5D-3L, pain/discomfort was 
the most important dimension in explaining respondents’ 
self-reported EQ-VAS scores in Japan (on average, a one 
level increase in the pain/discomfort dimension led to a 
decrease of 11.03 points on the EQ-VAS), whereas in the 
UK, it was the dimension of usual activities. Using EQ-
5D-5L data, anxiety/depression was the most important 
dimension in explaining differences in EQ-VAS scores in 
England and Spain; however, in Japan, the most important 
dimension was usual activities. The adjusted R-squared and 
results from residual analyses for each model are reported 
in Table  3. The results from residual analyses suggest no 
evidence of multicollinearity in the five models. However, 
there is evidence of residuals with non-normal distribu-
tions, heteroscedasticity, and non-linear functional form for 
some specifications.
Table  4 reports the mean EQ-5D-3L TTO values for 
the 17 hypothetical health states valued by respondents in 
the UK and Japan. In Japan, none of the mean TTO values 
Fig. 1  The proportion of respondents in Japan and the UK who reported level one (no problems) by EQ-5D-3L dimension. MO mobility, SC 
self-care, UA usual activities, PD pain/discomfort, AD anxiety/depression
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for the 17 health states were below zero (i.e., none of them 
were considered as being worse than dead). By contrast, 
six of the 17 health states in the UK had negative mean 
TTO values. TTO values for the five mildest health states 
(11112, 11121, 11211, 12111, 21111) were lower in Japan 
than in the UK, with the differences being statistically 
significant at the 5% significance level. However, Japanese 
TTO values for the remaining 12 more severe health states 
were all higher than UK values for those health states. 
The differences were statistically significant at the 5% sig-
nificance level for 11 health states, but not for health state 
22222.
Fig. 2  The proportion of respondents in Japan, England, and Spain 
reporting level one (no problems) by EQ-5D-5L dimension. MO 
mobility, SC self-care, UA usual activities, PD pain/discomfort, AD 
anxiety/depression. Data on the pain/discomfort dimension for Eng-
land include those adjusted by age distribution of Japan (Japan age) 
and Spain (Spain age)
Table 3  Modeling self-reported EQ-VAS scores by country and EQ-5D version
Note: (1) Shapiro–Wilk test rejected the null hypothesis of normally distributed residuals in all five regressions at the 5% significance level. (2) 
The Breusch–Pagan test accepted the null hypothesis that the variance of the residuals is homogeneous at the 5% significance level for the Japan 
EQ-5D-3L model, but rejected the null hypothesis in all other four models. (3) The regression equation specification error test (RESET) rejected 
the null hypothesis of linear functional form for the specifications in Japan EQ-5D-5L model and Spain EQ-5D-5L model at the 5% significance 
level. (4) None of the five models indicated issues with multicollinearity (mean variance inflation factor < 3)
a Adjusted R-squared is computed using the formula 1 − [(1 − Rsq) × (N − 1)/(N − k − 1)], where Rsq represents R-squared (the proportion of vari-
ance in the dependent variable that can be explained by the independent variables); N represents the number of observations; and k represents 
the number of independent variables
Japan EQ-5D-3L UK EQ-5D-3L Japan EQ-5D-5L England EQ-5D-5L Spain EQ-5D-5L
Coef P value Coef P value Coef P value Coef P value Coef P value
Mobility −0.88 0.785 −5.87 0.000 −2.87 0.029 −3.46 0.000 −0.35 0.719
Self-care −5.42 0.394 −6.82 0.000 −4.41 0.128 −0.21 0.836 −3.29 0.065
Usual activities −9.50 0.018 −8.54 0.000 −9.61 0.000 −4.87 0.000 −5.86 0.000
Pain/discomfort −11.03 0.000 −6.80 0.000 −4.53 0.000 −3.28 0.000 −4.59 0.000
Anxiety/depression −7.22 0.003 −8.02 0.000 −5.83 0.000 −6.96 0.000 −7.87 0.000
Constant 115.80 0.000 125.80 0.000 114.94 0.000 105.99 0.000 109.82 0.000
Adjusted R-squareda 0.2027 0.4226 0.2285 0.5031 0.4026
N 543 3372 1026 996 1000
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Table  5 reports the mean EQ-5D-5L TTO values for 
the 86 hypothetical health states valued by respondents 
in Japan and England. For respondents in both countries, 
only the worst state 55555 was assigned a mean TTO value 
below zero. Mean TTO values were higher in Japanese 
respondents for 63 of the 86 hypothetical health states, 
with 19 of those differences being statistically significant 
(P < 0.05). No clear pattern was observed between the 
severity of health states and the presence of higher values 
from Japanese respondents; the 19 health states included 
mild states (e.g., 11112) and severe states (e.g., 55555). 
In only one case was a statistically significant higher value 
observed for English raters (state 35332).
Three pairs of health states in the EQ-5D-3L valua-
tion data in the UK and Japan differed only on the pain/
discomfort dimension. Analysis of those states showed that 
Japanese respondents traded off less time to avoid problems 
in the pain/discomfort dimension than UK respondents. 
The biggest between-country difference in mean TTO val-
ues was reported between health states 11121 and 11131, 
which would represent a decrease of 0.65 in TTO values in 
the UK compared with 0.15 in Japan.
Seven pairs of health states in the EQ-5D-5L in the 
English and Japanese valuation studies differed only in 
the pain/discomfort dimension. Specifically, four pairs dif-
fered between level 1 (no problem) and level 2 (mild prob-
lem), two pairs differed between level 1 (no problem) and 
level 4 (severe problem), while one pair differed between 
level 3 (moderate problem) and level 4 (severe problem). 
Comparing the mean TTO values between respondents in 
the two countries showed that Japanese respondents traded 
off either similar or less time to avoid problems in pain/
discomfort than English respondents. The biggest differ-
ence in mean TTO values was reported between health 
states 12334 and 12344, which would represent a decrease 
of 0.19 in TTO values in England compared with 0.10 in 
Japan.
Regression analysis of the linked self-reported and valu-
ation datasets showed that respondents’ self-reported pain/
discomfort was not significant in explaining the TTO val-
ues in Japan for EQ-5D-3L (P = 0.395) and EQ-5D-5L 
(P = 0.299), nor the UK for EQ-5D-3L (P = 0.159). How-
ever, it has significant positive effect in explaining the EQ-
5D-5L TTO values in England (P < 0.05).
Discussion
This is the first study to carry out an in-depth examina-
tion of the comparability of EQ-5D self-rated health status 
and valuation data from Japanese and European respond-
ents, with a particular focus on pain/discomfort. A number 
of findings were clear from the empirical analyses in this 
study.
First, respondents in Japan tend to report better health 
in general than respondents in England/UK and Spain. 
Second, with respect to pain/discomfort, respondents in 
Japan reported problems less frequently than respondents 
in England/UK, but slightly more frequently than respond-
ents in Spain. Third, Japanese respondents used a much 
smaller number of health states to describe their health than 
respondents in either of the other two countries, and Span-
ish respondents also used substantially fewer health states 
than respondents in England. Fourth, in the EQ-5D-3L 
valuation study, respondents in Japan were more will-
ing to trade off time for the mildest health states, but less 
willing to trade off time for the severe health states com-
pared with respondents in the UK. For nearly three-fourths 
of the EQ-5D-5L health states for which values were 
obtained, Japanese respondents’ values were higher than 
those from English respondents. However, in contrast with 
EQ-5D-3L values, there was no clear pattern between this 
and the severity of the states. Fifth, in the EQ-5D-3L and 
EQ-5D-5L valuation studies, Japanese respondents were 
willing to trade off less time to avoid problems in the pain/
discomfort dimension than respondents in England/UK. 
However, the differences in TTO values between respond-
ents in Japan and England are much smaller than in the EQ-
5D-3L valuation study.
It is not clear where these differences stem from, though 
similar findings have been reported previously. For exam-
ple, in a comparison of EQ-5D results from 20 countries 
Table 4  Comparing the mean TTO values for the 17 hypothetical 
EQ-5D-3L health states between respondents in Japan and the UK
*Significant at the 5% significance level
Health state Japan UK t statistics
11112 0.79 0.83 −2.90*
11121 0.79 0.85 −5.13*
11211 0.82 0.87 −4.73*
12111 0.81 0.83 −1.90*
21111 0.78 0.88 −8.05*
11113 0.71 0.39 12.36*
11131 0.64 0.20 15.81*
11312 0.64 0.55 4.01*
11133 0.54 −0.05 20.37*
13311 0.60 0.35 9.74*
32211 0.33 0.15 5.90*
22222 0.51 0.50 0.41
23232 0.41 −0.09 17.54*
32223 0.22 −0.17 13.86*
32313 0.21 −0.15 12.83*
33323 0.09 −0.39 18.81*
33333 0.01 −0.54 29.15*
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in a diabetes clinical trial, researchers found substantial 
variation in the reporting of functional health problems, 
but noted that the variation could not be explained by dif-
ferences in demographic variables, clinical risk factors, 
or rates of complications [22]. They suggested that the 
unexplained variability meant there were important prob-
lems of comparability across settings.
One possible cause of the differences found here is 
that the way terms used to describe health, e.g., the sever-
ity labels, varies across countries. For example, Luo 
Table 5  Comparing the 
mean TTO values for the 86 
hypothetical EQ-5D-5L health 
states between respondents in 
Japan and England
*Significant at the 5% significance level
Health state Japan England t statistics Health state Japan England t statistics
11112 0.91 0.85 2.41* 31524 0.46 0.45 0.18
11121 0.90 0.89 0.71 31525 0.39 0.43 −0.58
11122 0.86 0.79 2.15* 32314 0.52 0.51 0.23
11211 0.91 0.89 0.83 32443 0.45 0.29 2.48*
11212 0.81 0.82 -0.23 33253 0.41 0.40 0.04
11221 0.85 0.84 0.13 34155 0.36 0.24 1.70
11235 0.60 0.53 1.24 34232 0.53 0.55 −0.45
11414 0.60 0.41 3.23* 34244 0.34 0.26 1.23
11421 0.72 0.65 1.49 34515 0.30 0.32 −0.26
11425 0.54 0.53 0.09 35143 0.40 0.27 2.02*
12111 0.89 0.87 1.26 35245 0.30 0.18 1.89
12112 0.82 0.81 0.13 35311 0.60 0.51 1.60
12121 0.87 0.81 1.72 35332 0.38 0.59 −3.28*
12244 0.50 0.32 2.73* 42115 0.48 0.41 1.14
12334 0.61 0.44 2.55* 42321 0.59 0.54 0.89
12344 0.51 0.25 3.63* 43315 0.39 0.42 −0.37
12513 0.61 0.61 −0.01 43514 0.31 0.36 −0.70
12514 0.53 0.44 1.51 43542 0.33 0.23 1.50
12543 0.47 0.32 2.22* 43555 0.13 0.06 1.05
13122 0.75 0.81 −1.34 44125 0.38 0.32 0.78
13224 0.61 0.49 2.14* 44345 0.23 0.21 0.17
13313 0.63 0.69 −1.13 44553 0.17 0.09 1.06
14113 0.70 0.69 0.31 45133 0.49 0.36 1.85
14554 0.31 0.15 2.18* 45144 0.32 0.17 2.39*
15151 0.54 0.42 2.08* 45233 0.36 0.33 0.43
21111 0.90 0.89 0.37 45413 0.32 0.34 −0.32
21112 0.81 0.83 −0.39 51152 0.36 0.35 0.19
21315 0.60 0.54 1.02 51451 0.33 0.26 1.08
21334 0.54 0.50 0.50 52215 0.40 0.35 0.78
21345 0.42 0.43 −0.18 52335 0.32 0.33 −0.09
21444 0.40 0.15 3.93* 52431 0.43 0.54 −1.79
22434 0.45 0.53 −1.24 52455 0.15 0.07 1.07
23152 0.49 0.39 1.42 53221 0.58 0.58 −0.03
23242 0.52 0.44 1.30 53243 0.36 0.23 1.94
23514 0.54 0.40 2.29* 53244 0.26 0.12 2.00*
24342 0.46 0.36 1.48 53412 0.36 0.44 −1.23
24443 0.38 0.33 0.80 54153 0.28 0.27 0.22
24445 0.30 0.16 2.13* 54231 0.40 0.40 −0.05
24553 0.22 0.33 −1.49 54342 0.34 0.18 2.17*
25122 0.55 0.52 0.40 55225 0.21 0.17 0.52
25222 0.57 0.59 −0.54 55233 0.27 0.28 −0.06
25331 0.56 0.53 0.47 55424 0.17 0.25 −1.05
31514 0.45 0.39 0.98 55555 −0.02 −0.08 2.69*
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et  al. found that the interpretation and use of EQ-5D-5L 
response labels (e.g., ‘slight’, ‘moderate’, and ‘severe’) 
varied across Chinese, Malay, and English speakers in 
Singapore [23], whereas the English version gave similar 
outcomes in Chinese and non-Chinese English speakers in 
the same country [24], suggesting that there was no effect 
of culture on responses. Although a strict protocol is fol-
lowed in producing other language versions of EQ-5D [25], 
it may not always be possible to find identical terms in all 
languages. There is also evidence suggesting that Japanese 
respondents might be less willing to report pain than those 
in Europe, possibly due to a tendency within the Japanese 
culture for pain to be repressed and controlled rather than 
shared or expressed [26].
Our findings on the reporting of pain/discomfort coin-
cide with those of earlier multi-country studies that showed 
a tendency towards lower rates or intensity of self-reported 
pain in Japan than in other countries [7, 8, 27]. Despite 
lower rates of self-reported pain/discomfort in Japan, 
we found that this was the most important dimension in 
explaining respondents’ self-reported EQ-5D-3L VAS 
scores. There are two possible explanations for this dis-
crepancy. First, while the EQ-VAS scores and self-reported 
EQ-5D profiles measure how good or bad respondents rate 
their currently experienced health status, the TTO valua-
tion task evaluates health states that are hypothetical to the 
respondents. Second, the tasks involved EQ-VAS scores 
rating and TTO valuation, which are individually very dif-
ferent. It is possible for a respondent to rate a health state 
as poor on the EQ-VAS, but still not be willing to trade off 
any life years to avoid it (e.g., because of religious beliefs 
about the sanctity of life, being the primary caregiver to a 
small child, or having a very low personal discount rate). 
As the EQ-5D profile variables are treated as continu-
ous, the importance of each EQ-5D dimension in explain-
ing the EQ-VAS reflects the average effect in a dimension 
between two neighboring levels. An alternative approach is 
to treat the EQ-5D profile variables as dummies (i.e., one 
for each level and dimension). However, this would leave 
some categories with rather small sample sizes, particularly 
for severe levels (n < 5). Those results from the EQ-5D-3L 
data were not confirmed using EQ-5D-5L data. Given the 
design of the current study, it was not possible to determine 
whether the difference in findings was due to changes in 
methods or perceptions of the importance of pain/discom-
fort over time. It should also be noted that the lowest rates 
of pain/discomfort were observed in Spain. Other stud-
ies have also reported relatively low rates of self-reported 
problems on the EQ-5D descriptive system in the general 
population in Spain compared with other European coun-
tries although not on the EQ-VAS [10]. Similar findings 
have been reported for Spain using other instruments, such 
as the Brief Pain Inventory [28].
The comparison of valuation data also showed differ-
ences between countries. The Japanese EQ-5D-3L valu-
ation data showed a tendency to compress towards the 
middle of the scale. A mid-range response style and lower 
levels of extreme response style have been reported in some 
studies in Japanese subjects [29–31], though it is not clear 
whether such an effect may also be present in valuation 
studies. Furthermore, we found that respondents in Japan 
were less willing to trade off time to avoid pain/discomfort 
on the EQ-5D-3L than respondents in the UK. It should 
be noted that the 17 health states valued by the Japanese 
respondents were a subset of the health states in the UK 
valuation study. The TTO values may be influenced by 
the mix of severity in the set of states presented. This may 
affect observed differences in TTO values.
This compression of values in Japan relative to UK val-
ues was no longer observed when analyzing results from 
the EQ-5D-5L. Only the worst state (i.e., 55555) was rated 
worse than death in both countries. Almost three-quarters 
of the EQ-5D-5L health states were given higher values 
by Japanese respondents compared with English respond-
ents, indicating more reluctance to trade off time among 
Japanese respondents. However, unlike with the EQ-5D-3L 
data, these higher ratings were spread across all levels 
of severity. It is possible that these differences are due to 
changes in the methods that were used in the TTO valua-
tion tasks between the two versions of EQ-5D, or changes 
in perceptions of health states, and/or relative importance 
assigned to different dimensions over time. However, it is 
not possible to answer it definitively here.
Limitations
Ideally, samples from Japan and European countries used 
to explore differences in the self-reporting and valuation of 
pain would have identical distributions for all factors that 
might influence results. However, it was not possible to 
control for all relevant variables, although we controlled for 
the effects of age and gender. It remains unclear whether 
differences in the rates of health problems between coun-
tries and other unobserved characteristics may have led to 
the differences we observed.
Furthermore, the EQ-5D-3L data used in this study were 
collected in the 1990s and may no longer be applicable to 
the present populations in the UK and Japan; however, we 
do not consider this to be a limitation of the present anal-
ysis as we were interested in comparing results between 
countries and not in exploring whether the data collected 
then would be relevant today. The fact that it was possi-
ble to compare findings from two different variants of the 
instrument at two different time points could in fact be con-
sidered a strength of the study because it gives an indica-
tion of the robustness of the results.
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The possible misspecifications for modeling EQ-
VAS scores by the EQ-5D dimensions should be noted. 
Although the assumption of normality does not hold in 
the five models and, as a consequence, will have an impact 
on the P values, the estimated coefficients themselves will 
still be consistent. Four models reported heteroscedasticity 
in the residuals and two models reported non-linear func-
tional forms. These misspecifications might be explained 
by variables that are not included in modeling the EQ-VAS, 
but have an impact on the EQ-VAS, such as other health 
dimension(s) that are not covered by EQ-5D. If those vari-
ables are correlated with the EQ-5D dimensions, our esti-
mated coefficients could be biased. Similar issues have 
been observed in previous studies [18, 32, 33].
Finally, only data from two European countries were 
available for the present study and it is not clear whether 
results can be extrapolated to respondents in other Western 
countries.
Implications
Our findings have a number of implications. First, care 
should be taken when comparing and aggregating clinical 
data on pain between different countries, because respond-
ents may use different criteria when responding, which 
could potentially lead to the same treatment being more 
or less effective in different countries. Second, the differ-
ences between respondents in Japan and European coun-
tries in self-reported and valuation behaviors could have 
a substantial effect on the results of cost–utility analyses. 
For instance, while applying the EQ-5D-3L instrument, 
the compression of values on the utility scale and the bet-
ter baseline pain scores observed in Japan may result in 
relatively small improvements with treatment. Third, what 
constitutes a minimally important difference for EQ-5D 
index may be different between Japan and other coun-
tries. Fourth, if the findings related to pain/discomfort also 
applied to other pain measures used as inclusion criteria 
for clinical trials, then they might lead to questions about 
whether identical inclusion criteria for clinical trials are in 
fact being used across countries.
Conclusions
This study provides prima facie evidence of differences 
between Japan, UK/England, and Spain in the self-report-
ing and valuation of health, including pain/discomfort, 
when using EQ-5D in general population samples. The 
findings suggest the need for caution when comparing 
and/or aggregating EQ-5D data across the countries. Spe-
cifically designed studies, including the use of qualitative 
research and vignette techniques [34], would be helpful in 
exploring these issues further and confirming the findings.
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